travoprost ophthalmic / Generic mfg. - LARVOL DELTA

Retinal Pigment Epithelial Detachment Following Topical Travoprost Therapy. (PubMed, J Curr Glaucoma Pract) - "The absence of clinical or OCT features suggestive of alternative diagnoses-such as central serous chorioretinopathy, age-related macular degeneration, or pachychoroid spectrum disorders-combined with consistent reversibility, suggests a possible association between travoprost and RPED. These findings emphasize the importance of early recognition and timely intervention, as RPED appears fully reversible when identified promptly, preventing potential persistent visual impairment."

Journal • Age-related Macular Degeneration • Glaucoma • Macular Degeneration • Ophthalmology • Retinal Disorders

Sustained-Release Intracameral Prostaglandin Analog Implants for Glaucoma: Comparative Review and Meta-Analysis of Bimatoprost and Travoprost Delivery Systems. (PubMed, J Ocul Pharmacol Ther) - "Sustained-release intracameral prostaglandin implants provide durable IOP reduction while decreasing dependence on topical therapy. Although efficacy differences between travoprost and bimatoprost implants appear modest, their safety profiles differ, particularly regarding corneal endothelial effects. Further long-term comparative studies are warranted."

Journal • Retrospective data • Review • Cardiovascular • Glaucoma • Ophthalmology

Omidenepag isopropyl (Omlonti) for glaucoma. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Glaucoma • Ophthalmology

Pascal selective laser trabeculoplasty (PSLT) in the treatment of ocular hypertension and open-angle glaucoma compared to travoprost eye drops: A non-inferiority clinical trial. (PubMed, PLoS One) - P=N/A | "PSLT was as effective as prostaglandin eye drops in reducing IOP and IOP peak in POAG and OHT patients. These findings are especially important as interest grows in minimally invasive glaucoma treatments and reducing reliance on topical medications."

Clinical • Head-to-Head • Journal • Cardiovascular • Glaucoma • Ophthalmology

The paradox of treatment: Ciliary effusion induced by travoprost - A case report. (PubMed, Am J Ophthalmol Case Rep) - "Significant resolution occurred within one week after discontinuing travoprost. Isolated ciliary effusion should be recognized as a rare adverse effect of travoprost, with drug discontinuation playing both diagnostic and therapeutic roles."

Journal • Achromatopsia • Glaucoma • Ophthalmology

A Comprehensive Review of the Clinical Evidence Comparing Benzalkonium Chloride-Preserved and Benzalkonium Chloride-Free Latanoprost in the Treatment of Primary Open-Angle Glaucoma and Ocular Hypertension. (PubMed, Clin Ophthalmol) - "Inclusion criteria were peer-reviewed clinical trials and meta-analyses comparing latanoprost with placebo or other treatments (eg. bimatoprost, travoprost, tafluprost, latanoprostene bunod)...Comparative studies indicate that latanoprost achieves a good balance between IOP reduction and tolerability compared to bimatoprost, travoprost, tafluprost, and unoprostone...Latanoprost remains a first-line therapy for POAG and OHT due to its efficacy, safety, and patient adherence. The availability of BAK-free formulations enhances its therapeutic profile, with reduced corneal toxicity making it a preferred choice for long-term glaucoma management."

Clinical • Journal • Review • Cardiovascular • Dermatology • Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain

Travoprost Intraocular Implant + iStent Infinite (clinicaltrials.gov) - P4 | N=150 | Recruiting | Sponsor: Glaukos Corporation | Phase classification: P3 ➔ P4 | N=230 ➔ 150

Enrollment change • Phase classification • Cardiovascular • Glaucoma • Ophthalmology

Efficacy and safety of netarsudil compared with prostaglandin-based therapies: a Bayesian network meta-analysis. (PubMed, Int Ophthalmol) - "The study aimed to compare the efficacy and safety of netarsudil (NET), alone or in fixed-dose combinations (FDC), in comparison with prostaglandin analogues (PGAs: bimatoprost [BIM], latanoprost [LAT], travoprost [TRA], and tafluprost [TAF]) for the treatment of primary open-angle glaucoma (POAG) or ocular hypertension. Although NET ranked lower in IOP-lowering efficacy compared to most PGAs and FDC, it demonstrated a favorable safety profile, particularly with a relatively lower incidence of conjunctival hyperemia than TAF and FDC. These findings suggest that NET may serve as a valuable alternative in patients who are intolerant to PGAs or require adjunctive therapy, warranting further investigation in targeted populations."

Clinical • Journal • Retrospective data • Cardiovascular • Glaucoma • Ophthalmology

Shifting Medicare Glaucoma Pharmacotherapy: Rising Costs and Increasing Use of New Mechanism Agents, 2019-2023 (ARVO 2026) - "Results From 2019-2023, utilization of several legacy agents declined sharply (e.g., Travatan Z from 291,097 to 7,534 claims; Combigan from 282,811 to 144,502 claims), while medications with new mechanism of action demonstrated steady growth, including Rhopressa (60,538 to 89,044 claims), Rocklatan (13,994 to 67,255 claims), and Vyzulta (21,280 to 69,308 claims)...Spending (market) shares showed parallel shifts: Lumigan decreased from 54% to 43% and Combigan from 33% to 14%, while medications with new mechanisms of action captured a growing share of total Medicare glaucoma spending – Rhopressa increasing from 7.1% to 10.7%, Rocklatan from 1.1% to 9.0%, and Vyzulta from 2.2% to 7.2%...Total spending rose nearly 50% despite declining overall utilization, underscoring the growing cost burden associated with newer, higher-cost branded agents. These findings highlight the need for cost-conscious prescribing strategies and further evaluation of affordability and access in..."

Medicare • Reimbursement • US reimbursement • Glaucoma • Ophthalmology

Post-Marketing Surveillance Reveals Amplified Adverse Event Burden Across Topical Pharmacotherapies for Primary Open-Angle Glaucoma (ARVO 2026) - "The FDA-approved drugs evaluated included bimatoprost, tafluprost, travoprost, latanoprost, omidenepag, timolol, brimonidine, brinzolamide, dorzolamide, netarsudil, brinzolamide-brimonidine, and brimonidine-timolol. With average trial lengths of 15 months versus chronic real-world use, post-marketing data reveal multisystem and mortality-associated safety signals not detected pre-approval. These findings highlight gaps in the POAG trial safety reporting and may support the need for extended pharmacovigilance beyond formal trial periods."

Adverse events • P4 data • Glaucoma • Ophthalmology

Prostaglandin Analogs and Glaucoma Eye Drop Prescription Patterns in Medicare Part D from 2014 to 2023 (ARVO 2026) - "Within the prostaglandin analog class, latanoprost was the most prescribed drug, whereas Lumigan incurred the highest annual cost...Additionally, Travatan Z maintained the second-highest total cost until a marked decline beginning in 2020, coinciding with the introduction of its generic version, Travoprost...The two most influential drugs affecting total cost were brand-name prostaglandins, one with a recently introduced generic and one without. This divergence in claims and cost trends highlights how prescription volume is primarily driven by disease prevalence, whereas drug cost is more strongly influenced by pharmaceutical cost."

Medicare • Reimbursement • US reimbursement • Glaucoma • Ophthalmology

A new Travoprost formulation containing hyaluronic acid improves ocular penetration while reducing systemic exposure and dry eye signs in preclinical studies (ARVO 2026) - "In the dry eye model, TP+HA treatment was associated with significantly better tear stability and better staining scores compared to commercial TP (TBUT: 2.64±0.92s vs. 0.85±0.86s, p=0.0001; FS: 2.85±1.35 vs. 4.57±1.69, p=0.0057). Conclusions This new TP+HA formulation represents a promising alternative to existing commercial glaucoma treatments as it delivers a therapeutic concentration of TP in the target tissue, while at the same time it may improve dry eye signs and reduce the ocular side effects often observed in patients treated with antiglaucoma medications."

Preclinical • Dry Eye Disease • Glaucoma • Ophthalmology

NEUROPA: Retinal Ganglion Cell Neuroprotection Under Prostaglandin Analogues (clinicaltrials.gov) - P=N/A | N=1500 | Not yet recruiting | Sponsor: Association for Innovation and Biomedical Research on Light and Image | Initiation date: Jan 2026 ➔ May 2026

Trial initiation date • Glaucoma • Ophthalmology

Regional variation and trends in prostaglandin analogue prescribing for glaucoma in England 2019-2024. (PubMed, Eye (Lond)) - "Regional variation in PGA prescribing exists in England. Further investigation is required to determine the primary cause for the reported differences. Reducing variations so that prescribing clinicians are directed towards the most cost-effective PGA choice has the potential for considerable cost savings to NHS budgets."

Journal • Glaucoma • Ophthalmology

Beyond pressure control: Periorbital impact of prostaglandins vs. laser trabeculoplasty. (PubMed, Arq Bras Oftalmol) - "Chronic use of prostaglandin analogs is associated with notable periorbital changes and increased lower eyelid tension, potentially affecting aesthetics and ocular function. Pascal selective laser trabeculoplasty may offer a safer profile for preserving periorbital anatomy while maintaining effective intraocular pressure control. Laser trabeculoplasty should be considered as an initial treatment when appropriate to minimize cosmetic and functional changes from chronic topical therapy."

Clinical • Journal

Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone (clinicaltrials.gov) - P3 | N=230 | Recruiting | Sponsor: Glaukos Corporation | N=150 ➔ 230 | Trial completion date: Nov 2025 ➔ Feb 2028 | Trial primary completion date: Feb 2025 ➔ May 2027

Enrollment change • Trial completion date • Trial primary completion date • Cardiovascular • Glaucoma • Ophthalmology

Implants to Treat Glaucoma: Promising or Not? (PubMed, Drugs Aging) - "The biodegradable bimatoprost implant releases the drug continuously for 4-6 months, and its effect on IOP may extend for up to 2 years in 25% of patients. The non-biodegradable intracameral implant releases travoprost for 36 months, when it needs to be removed...Several other biodegradable intracameral implants that release prostaglandin analogues are undergoing clinical trials. In the future, intraocular implants containing genetically modified cells that secrete neurotrophic factors may potentially offer an IOP-independent neuroprotective strategy, complementing existing IOP-lowering implants in glaucoma management."

Journal • Review • Glaucoma • Ocular Inflammation • Ophthalmology • Optic Neuritis • Pain

Impact of Preservative-Free Travoprost on Intraocular Pressure and Ocular Surface in Primary Open-Angle Glaucoma Patients. (PubMed, Life (Basel)) - "Preservative-free travoprost effectively reduces IOP while improving ocular surface health, particularly in tear production and conjunctival hyperemia."

Journal • Cardiovascular • Glaucoma • Ophthalmology

Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Travoprost Ophthalmic Solution USP, 0.004% (Ionic Buffered Solution), marking another addition to its growing US generics portfolio. (Business Upturn)

ANDA • Ophthalmology

Evaluation of Travoprost Prescribing and Safety in the Management of Glaucoma at VA Southern Oregon Rehabilitation Center and Clinics (SORCC) (ASHP 2025) - No abstract available

Clinical • Glaucoma • Ophthalmology

Travoprost intraocular implants: pioneering a new approach in ocular hypertension management. (PubMed, Ann Med Surg (Lond)) - "While travoprost, a highly effective topical prostaglandin FP analogue, is frequently prescribed for patients with increased intraocular pressure, it presents challenges such as complex dosing regimens, poor adherence, and an increased risk of side effects stemming from chronic topical use. This comprehensive narrative review systematically investigates the contemporary status of travoprost intraocular implant, a device specifically engineered for sustained drug delivery to overcome the limitations of conventional topical travoprost formulations.The review synthesizes findings from studies discussing these implants and critically analyses the safety, efficacy profiles and patient tolerability detailed, including the two recent Phase 3 trials that led to its FDA approval, contextualizing them against other treatment modalities and therapies.While the advent of the iDose TR device marks a significant mark in the treatment and management of glaucoma and OHT, this review..."

Journal • Review • Cardiovascular • Glaucoma • Ophthalmology

Severe Microbial Keratitis Secondary to Prostaglandin-Associated Periorbitopathy. (PubMed, Case Rep Ophthalmol Med) - "Prostaglandin-associated periorbitopathy (PAP) is a known complication of prostaglandin therapy most commonly associated with topical bimatoprost...The authors report a case of PAP-induced lagophthalmos and secondary microbial keratitis that necessitated a corneal graft. Reversal of these findings occurred on prostaglandin cessation with dramatic reversal of findings within 8 weeks."

Journal • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • Transplantation

The Effect of Preoperative Use of High- vs. Low-PAP-Inducing-Potential FP Agonists on the Surgical Outcomes of Trabeculectomy and AGV Implantation. (PubMed, J Clin Med) - "The eyes were stratified by preoperative FP agonist use into the high-PAP-inducing-potential (bimatoprost or travoprost) and low-PAP-inducing-potential (latanoprost or tafluprost) groups. Although the effect on AGV implantation appears limited, it may still influence early postoperative results. These findings underscore the need to consider PAP risk and medication history when selecting surgical procedures for glaucoma."

Journal • Glaucoma • Ophthalmology

Management of ocular adverse reactions to antiglaucoma medications-Survey of optometrists in Ghana. (PubMed, PLOS Glob Public Health) - "Latanoprost (32.2%), timolol (23.7%), travoprost (17.6%), and brimonidine (10.2%) were the medications most frequently associated with these reactions. These findings highlight that although OADRs are common in glaucoma management, optometrists in Ghana often lack standardized protocols and report low confidence in handling such cases. Targeted professional development and refresher training are needed to strengthen OADRs recognition, reporting, and management, ultimately improving patient eye care."

Journal • Dry Eye Disease • Glaucoma • Ophthalmology

Progressive Visual Field Loss in the Setting of Severe Orbital Fat Atrophy. (PubMed, Cureus) - "This study explores the complex case of an 81-year-old female with primary open-angle glaucoma, initially treated with travoprost...This case highlights the complex nature of glaucoma management, emphasizing the impact of mechanical stress on the optic nerve and the role of prostaglandin-induced orbital atrophy. The findings underscore the importance of personalized approaches, considering both pharmacological effects and individual anatomical variations."

Journal • Glaucoma • Hematological Disorders • Obstructive Sleep Apnea • Ophthalmology • Respiratory Diseases • Sleep Apnea • Sleep Disorder